Please enter a valid month/year e.g. 01/2015

Pick a date between March 2000 and July 2017

Showing 1 to 10 of 341
Title Reference number Published Last updated
Carfilzomib for previously treated multiple myeloma Reference number:TA457 TA00457 Published:July 2017 20170701 Last updated:July 2017 20170719
Trastuzumab emtansine for treating HER2-positive advanced breast cancer after trastuzumab and a taxane Reference number:TA458 TA00458 Published:July 2017 20170701 Last updated:July 2017 20170719
Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people Reference number:TA455 TA00455 Published:July 2017 20170701 Last updated:July 2017 20170712
Ustekinumab for moderately to severely active Crohn’s disease after previous treatment Reference number:TA456 TA00456 Published:July 2017 20170701 Last updated:July 2017 20170712
Ibrutinib for untreated chronic lymphocytic leukaemia without a 17p deletion or TP53 mutation (terminated appraisal) Reference number:TA452 TA00452 Published:July 2017 20170701 Last updated:July 2017 20170705
Bortezomib for treating multiple myeloma after second or subsequent relapse (terminated appraisal) Reference number:TA453 TA00453 Published:July 2017 20170701 Last updated:July 2017 20170705
Daratumumab with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal) Reference number:TA454 TA00454 Published:July 2017 20170701 Last updated:July 2017 20170705
Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma Reference number:TA446 TA00446 Published:June 2017 20170601 Last updated:June 2017 20170628
Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer Reference number:TA447 TA00447 Published:June 2017 20170601 Last updated:June 2017 20170628
Etelcalcetide for treating secondary hyperparathyroidism Reference number:TA448 TA00448 Published:June 2017 20170601 Last updated:June 2017 20170628